Actively Recruiting
Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD
Led by The University of Hong Kong · Updated on 2026-04-27
112
Participants Needed
2
Research Sites
166 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this prospective, 24-week, double-masked, randomized, sham-controlled clinical trials to compare clinical efficacy and safety of RF and MGX with MGX alone in patients with meibomian gland dysfunction-related dry eye disease. The main question it aims to answer is whether radiofrequency treatment and meibomian gland expression is more effective in improving tear breakup time, as measured using non-invasive video keratography, compared with meibomian gland expression alone, in patients with refractory meibomian gland dysfunction-related dry eye disease. Participants will be divided into two groups, one group will receive RF treatment followed with MGX and another will receive sham treatment with MGX.
CONDITIONS
Official Title
Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Presence of dry eye symptoms and signs in both eyes confirmed by abnormal SPEED questionnaire score (≥5) and abnormal results in at least one clinical test (tear osmolarity, NIKBUT, or corneal staining)
- Bilateral moderate to severe meibomian gland dysfunction with at least Grade 1 meibum quality (cloudy appearance) and Grade 2 meibum expressibility (moderate pressure required)
- Refractory meibomian gland dysfunction defined as failure to respond to at least three types of conventional therapies (artificial tears, antibiotics, anti-inflammatory treatments, heat-based therapies) over at least 2 years
- Fitzpatrick skin type I to IV
- Mentally fit to provide informed consent
You will not qualify if you...
- Fitzpatrick skin type V or VI
- History of eyelid scarring
- Significant acinar gland atrophy (>30% dropout) seen on infrared meibography
- Pregnancy or breastfeeding
- Active corneal diseases such as infectious keratitis, allergic keratoconjunctivitis, pterygium, exposure keratopathy, lagophthalmos, trichiasis, or dellen
- Current use of photosensitive systemic medications such as tetracycline antibiotics
- History of corneal abnormality or surgery within the past 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Grantham Hospital
Hong Kong, Hong Kong
Actively Recruiting
2
HKU Eye Centre
Hong Kong, Hong Kong
Actively Recruiting
Research Team
K
Kendrick Co SHIH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here